Chris Viehbacher, Biogen CEO (Romuald Meigneux/Sipa via AP Images)
June 5, 2023 11:44 AM EDT
R&D

Bio­gen cuts PhI­II Parkin­son’s pro­gram over ‘long time­line’ 

Nicole DeFeudis

Editor

Bio­gen is call­ing it quits on a late-stage Parkin­son’s tri­al as part of an on­go­ing R&D re­or­ga­ni­za­tion.

The Cam­bridge, MA-based biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times